KRAS and familial pancreatic carcinoma: Fendiline, a calcium channel blocker, inhibited the explicit localization of KRAS at the membrane, which impacts the activation of AKT and ERK, as well as the reduction of c-myc and CD44 expression in the pancreatic cancer cell line (PANC1, MIAPACA2, CD18) [196,197].